A citation-based method for searching scientific literature

Maria Teresa Ricci, Stefania Sciallero, Serafina Mammoliti, Viviana Gismondi, Marzena Franiuk, Paolo Bruzzi, Liliana Varesco. Public Health Genomics 2015
Times Cited: 17







List of co-cited articles
148 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
696
58

Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.
Terri Febbraro, Katina Robison, Jennifer Scalia Wilbur, Jessica Laprise, Amy Bregar, Vrishali Lopes, Robert Legare, Ashley Stuckey. Gynecol Oncol 2015
65
47

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
41

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Tuya Pal, Jenny Permuth-Wey, Judith A Betts, Jeffrey P Krischer, James Fiorica, Hector Arango, James LaPolla, Mitchell Hoffman, Martin A Martino, Katie Wakeley,[...]. Cancer 2005
505
35

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.
Angela George, Daniel Riddell, Sheila Seal, Sabrina Talukdar, Shazia Mahamdallie, Elise Ruark, Victoria Cloke, Ingrid Slade, Zoe Kemp, Martin Gore,[...]. Sci Rep 2016
101
35

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Harvey A Risch, John R McLaughlin, David E C Cole, Barry Rosen, Linda Bradley, Isabel Fan, James Tang, Song Li, Shiyu Zhang, Patricia A Shaw,[...]. J Natl Cancer Inst 2006
447
29

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.
Shiyu Zhang, Robert Royer, Song Li, John R McLaughlin, Barry Rosen, Harvey A Risch, Isabel Fan, Linda Bradley, Patricia A Shaw, Steven A Narod. Gynecol Oncol 2011
246
29

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
875
29

The sooner the better: Genetic testing following ovarian cancer diagnosis.
E Fox, J McCuaig, R Demsky, C Shuman, D Chitayat, M Maganti, J Murphy, B Rosen, S Ferguson, S Randall Armel. Gynecol Oncol 2015
19
29

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Johnathan M Lancaster, C Bethan Powell, Lee-May Chen, Debra L Richardson. Gynecol Oncol 2015
160
29

Keeping it simple: genetics referrals for all invasive serous ovarian cancers.
R Demsky, J McCuaig, M Maganti, K J Murphy, B Rosen, S R Armel. Gynecol Oncol 2013
37
29

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
29

Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic.
Sue V Petzel, Rachel Isaksson Vogel, Tracy Bensend, Anna Leininger, Peter A Argenta, Melissa A Geller. J Genet Couns 2013
29
29

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y Karlan, Amit Amnon, Katherine M Bell-McGuinn, Lee-May Chen, Michael Friedlander,[...]. J Clin Oncol 2012
330
29

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
29

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
853
29

Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study.
Kelly A Metcalfe, Isabel Fan, John McLaughlin, Harvey A Risch, Barry Rosen, Joan Murphy, Linda Bradley, Susan Armel, Ping Sun, Steven A Narod. Gynecol Oncol 2009
44
23

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
H A Risch, J R McLaughlin, D E Cole, B Rosen, L Bradley, E Kwan, E Jack, D J Vesprini, G Kuperstein, J L Abrahamson,[...]. Am J Hum Genet 2001
718
23

There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer.
B Meiser, M Gleeson, N Kasparian, K Barlow-Stewart, M Ryan, K Watts, D Menon, G Mitchell, K Tucker. Gynecol Oncol 2012
30
23

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
778
23

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
952
23

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Tom Walsh, Silvia Casadei, Ming K Lee, Christopher C Pennil, Alex S Nord, Anne M Thornton, Wendy Roeb, Kathy J Agnew, Sunday M Stray, Anneka Wickramanayake,[...]. Proc Natl Acad Sci U S A 2011
582
23

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
J M Cunningham, M S Cicek, N B Larson, J Davila, C Wang, M C Larson, H Song, E M Dicks, P Harrington, M Wick,[...]. Sci Rep 2014
80
17

Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.
Sunil R Lakhani, Sanjiv Manek, Frederique Penault-Llorca, Adrienne Flanagan, Laurent Arnout, Samantha Merrett, Lesley McGuffog, Dawn Steele, Peter Devilee, Jan G M Klijn,[...]. Clin Cancer Res 2004
181
17

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J A Ledermann, F A Raja, C Fotopoulou, A Gonzalez-Martin, N Colombo, C Sessa. Ann Oncol 2013
402
17

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
509
17

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
David S P Tan, Christian Rothermundt, Karen Thomas, Elizabeth Bancroft, Rosalind Eeles, Susan Shanley, Audrey Ardern-Jones, Andrew Norman, Stanley B Kaye, Martin E Gore. J Clin Oncol 2008
328
17

Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
Janice S Kwon, Molly S Daniels, Charlotte C Sun, Karen H Lu. J Clin Oncol 2010
48
17

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
Angela George, Stan Kaye, Susana Banerjee. Nat Rev Clin Oncol 2017
90
17

Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer.
Joan L Walker, C Bethan Powell, Lee-May Chen, Jeanne Carter, Victoria L Bae Jump, Lynn P Parker, Mark E Borowsky, Randall K Gibb. Cancer 2015
141
17

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
M Moschetta, A George, S B Kaye, S Banerjee. Ann Oncol 2016
95
17

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
U A Matulonis, R T Penson, S M Domchek, B Kaufman, R Shapira-Frommer, M W Audeh, S Kaye, L R Molife, K A Gelmon, J D Robertson,[...]. Ann Oncol 2016
86
17

Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?
C Bethan Powell, Ramey Littell, Elizabeth Hoodfar, Fiona Sinclair, Alice Pressman. Int J Gynecol Cancer 2013
37
17

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
498
17

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
17


Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
849
17

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
17

Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario.
Jacob McGee, Karen Panabaker, Sean Leonard, Peter Ainsworth, Laurie Elit, Salimah Z Shariff. Int J Gynecol Cancer 2017
15
20

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.
Larissa A Meyer, Meaghan E Anderson, Robin A Lacour, Anuj Suri, Molly S Daniels, Diana L Urbauer, Graciela M Nogueras-Gonzalez, Kathleen M Schmeler, David M Gershenson, Karen H Lu. Obstet Gynecol 2010
83
17

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Bryan T J Hennessy, Kirsten M Timms, Mark S Carey, Alexander Gutin, Larissa A Meyer, Darl D Flake, Victor Abkevich, Jennifer Potter, Dmitry Pruss, Pat Glenn,[...]. J Clin Oncol 2010
247
17

Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling.
Morgan Butrick, Scott Kelly, Beth N Peshkin, George Luta, Rachel Nusbaum, Gillian W Hooker, Kristi Graves, Lisa Feeley, Claudine Isaacs, Heiddis B Valdimarsdottir,[...]. Genet Med 2015
61
17

Inherited Mutations in Women With Ovarian Carcinoma.
Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger,[...]. JAMA Oncol 2016
353
17

Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The "Opt-Out" Process.
Jacob McGee, Teresa M Peart, Norine Foley, Monique Bertrand, Michel Prefontaine, Akira Sugimoto, Helen Ettler, Stephen Welch, Karen Panabaker. J Oncol 2019
6
50


Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians.
Cecelia A Bellcross, Katherine Kolor, Katrina A B Goddard, Ralph J Coates, Michele Reyes, Muin J Khoury. Am J Prev Med 2011
113
11

Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
Jacqueline Mersch, Michelle A Jackson, Minjeong Park, Denise Nebgen, Susan K Peterson, Claire Singletary, Banu K Arun, Jennifer K Litton. Cancer 2015
267
11


Prediction of breast cancer risk based on profiling with common genetic variants.
Nasim Mavaddat, Paul D P Pharoah, Kyriaki Michailidou, Jonathan Tyrer, Mark N Brook, Manjeet K Bolla, Qin Wang, Joe Dennis, Alison M Dunning, Mitul Shah,[...]. J Natl Cancer Inst 2015
309
11

Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis.
Catherine M Olsen, Adèle C Green, David C Whiteman, Shahram Sadeghi, Fariba Kolahdooz, Penelope M Webb. Eur J Cancer 2007
165
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.